Of potential clinical interest is our finding that STAMP mRNA levels are elevated in human ovarian cancer samples (stages I-IV), although the effects of STAMP levels on ovarian cancer cell growth vary. This evidence concerns the gene TTLL5 and ovarian carcinoma.